Michael J. Haller, M.D., MS-CI

Michael Haller, MDDivision

Endocrinology

Academic Title

Professor and Chief
Silverstein Family Eminent Scholar
Pediatric Endocrinology
University of Florida

Contact Information

Phone: (352) 273-9264
Fax: (352) 294-8109
hallemj@peds.ufl.edu

Office

Biomedical Sciences Building, J-591

 

About

Dr. Michael Haller is a pediatric endocrinologist with a passion for patient care, teaching, and research. Mike is a Gainesville native and a proud graduate of the University of Florida’s College of Medicine, Pediatrics Residency, and Pediatric Endocrinology Fellowship Programs.  In addition to serving as the Pediatric Endocrinology Chief and Fellowship director, Dr. Haller coordinates an active research team focused on the prediction, prevention, and reversal of type 1 diabetes.

Dr. Haller is an active investigator in the NIH funded Type 1 Diabetes TrialNet, the NIH TEDDY study, and the T1D Exchange. Mike serves as the Co-PI of the University of Florida TrialNet Clinical Center, as the Chair of the Clinical Implementation Committee for the TEDDY study, and as Vice-President of the Florida Camp for Children and Youth with Diabetes.   Dr. Haller was the PI of “first in man” studies aimed at using autologous umbilical cord blood stem cells as a potential therapy for type 1 diabetes and more recently led a groundbreaking pilot study demonstrating the efficacy of Thymogloublin and Neulasta in patients with established type 1 diabetes. Dr. Haller now serves as the PI of a major TrialNet study aimed at confirming the efficacy of Thymoglobulin and Neulasta in new-onset type 1 diabetes patients.

Dr. Haller has published over 200 peer reviewed manuscripts and book chapters and in the last 5 years has received over $8.5 million dollars in research funding.  Mike has received the Henry Kokomor award, the Douglas Barrett award, the Pediatric Endocrine Society Clinical Scholar award, and the JDRF Early Career award. In 2008, Dr. Haller, and his colleagues Dr. Desmond Schatz and Dr. Mark Atkinson received the JDRF’s highest award, the Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award, for their team approach to developing therapies for type 1 diabetes.  In 2016, Dr. Haller took the reins from his long time mentor Dr. Janet Silverstein to become the Division Chief of the Pediatric Endocrinology Division at the University of Florida. In 2017, Dr. Haller was awarded both a UF Term Professorship and the prestigious UF Research Foundation Professorship.

Key Publications

Additional publications can be found in PubMed.

  1. Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease.
    Elding Larsson H, Vehik K, Gesualdo P, Akolkar B, Hagopian W, Krischer J, Lernmark Å, Rewers M, Simell O, She JX, Ziegler A, Haller MJ; TEDDY Study Group. Pediatr Diabetes. 2014
    Mar;15(2):118-26. doi: 10.1111/pedi.12066. Epub 2013 Aug 27.
  2. Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis.
    Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, Tamborlane WV, Lee JM, Haller MJ; Pediatric Diabetes Consortium.
    Pediatr Diabetes. 2014 Jun;15(4):287-93. doi: 10.1111/pedi.12068. Epub 2013 Aug 15.
  3. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.
    Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR, Theriaque DW, Shuster JJ, Ferguson RJ, Kozuch M, Clare-Salzler M, Atkinson MA, Schatz DA.
    Biol Blood Marrow Transplant. 2013 Jul;19(7):1126-9. doi: 10.1016/j.bbmt.2013.04.011. Epub 2013 Apr 20
  4. Type 1 diabetes: current concepts in epidemiology, pathophysiology, clinical care, and research.
    Gan MJ, Albanese-O’Neill A, Haller MJ.
    Curr Probl Pediatr Adolesc Health Care. 2012 Nov-Dec;42(10):269-91. doi: 10.1016/j.cppeds.2012.07.002. Review.
  5. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA. J Clin Invest. 2015 Jan;125(1):448-55. doi: 10.1172/JCI78492. Epub 2014 Dec 15.